

Further Patents for Cynata's Unique Cymerus™ Technology

Melbourne, Australia; 15 September 2021: Cynata Therapeutics Limited (ASX: "CYP", "Cynata", or the "Company"), a clinical-stage biotechnology company specialising in cell therapeutics, has today announced that the Patent Office of the Russian Federation (ROSPATENT) has accepted two patent applications and has provided notice that it intends to grant two new patents on those applications covering Cynata's proprietary Cymerus™ mesenchymal stem cell (MSC) technology. The matters are entitled "Pluripotent Stem Cell Assay" and "Colony Forming Medium and Use Thereof" and are wholly owned by Cynata.

These further Cynata patents will build on the broad IP protection of Cynata's manufacturing platform and its unique ability to yield highly consistent mesenchymal stem cells at scale, from a single donation, to create therapeutic stem cell products.

Dr Ross Macdonald, Cynata's Chief Executive Officer, said:

"Cynata continues to build meaningful value in its Cymerus™ stem cell technology platform through the advancement of its unique and proprietary intellectual property portfolio. The granting of two new Russian patents follows recent patent successes in the United States and in Canada, generating a substantial IP asset base in markets of major commercial importance. The Cymerus platform enables manufacture of consistent, high-quality mesenchymal stem cells at scale. This unique and valuable characteristic of Cynata's technology is key to the development of off-the-shelf therapeutic stem cell products to target a range of devastating diseases worldwide".

The new Russian patents are expected to grant in late 2021 and will have expiration dates in 2037.

-ENDS-

Authorised for release by Dr Ross Macdonald, Managing Director & CEO

CONTACTS: Dr Ross Macdonald, CEO, Cynata Therapeutics, +61 (0)412 119343, ross.macdonald@cynata.com

Lauren Nowak, Media Contact, +61 (0)400 434 299, laurenmaree@live.com.au

About Cynata Therapeutics (ASX: CYP)

Cynata Therapeutics Limited (ASX: CYP) is an Australian clinical-stage stem cell and regenerative medicine company focused on the development of therapies based on Cymerus™, a proprietary therapeutic stem cell platform technology. Cymerus™ overcomes the challenges of other production methods by using induced pluripotent stem cells (iPSCs) and a precursor cell known as mesenchymoangioblast (MCA) to achieve economic manufacture of cell therapy products, including mesenchymal stem cells (MSCs), at commercial scale without the limitation of multiple donors.

Cynata's lead product candidate CYP-001 met all clinical endpoints and demonstrated positive safety and efficacy data for the treatment of steroid-resistant acute graft-versus-host disease (GvHD) in a Phase 1 trial. Clinical trials of Cymerus MSC products in osteoarthritis (Phase 3) and in patients with respiratory failure are currently ongoing. Planning is also underway for further clinical trials of Cymerus MSC products in GvHD (through licensee Fujifilm), diabetic foot ulcers, critical limb ischemia, idiopathic pulmonary fibrosis, and renal transplantation. In addition, Cynata has demonstrated



utility of its Cymerus MSC technology in preclinical models of numerous diseases, including the clinical targets mentioned above, as well as asthma, heart attack, sepsis, acute respiratory distress syndrome (ARDS) and cytokine release syndrome.

Cynata Therapeutics encourages all current investors to go paperless by registering their details with the designated registry service provider, Automic Group.